KAMADA LTD. Inactive Instrument
Kamada Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
IL0010941198
Pharmaceuticals
| Sales 2024 * | 573M 152M 57.34B 12.1B | Sales 2025 * | 706M 187M 70.6B 14.9B | Capitalization | 1.11B 295M 111B 23.51B |
|---|---|---|---|---|---|
| Net income 2024 * | 46M 12.17M 4.6B 971M | Net income 2025 * | 84M 22.22M 8.4B 1.77B | EV / Sales 2024 * | 1.94 x |
| Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 08/12/13 |
David Tsur
FOU | Founder | 73 | 12/12/90 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 30/12/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 23/12/19 |
Leon Recanati
BRD | Director/Board Member | 76 | 30/04/05 |
David Tsur
FOU | Founder | 73 | 12/12/90 |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +56.59% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
